Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Preliminary studies suggested that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa L., might be effective in the treatment of Tourette syndrome (TS). This study was performed to investigate for the first time under controlled conditions, over a longer-term treatment period, whether THC is effective and safe in reducing tics in TS. Method In this randomized, double-blind, placebo-controlled study, 24 patients with TS, according to DSM-III-R criteria, were treated over a 6-week period with up to 10 mg/day of THC. Tics were rated at 6 visits (visit 1, baseline; visits 2-4, during treatment period; visits 5-6, after withdrawal of medication) using the Tourette Syndrome Clinical Global Impressions scale (TS-CGI), the Shapiro Tourette-Syndrome Severity Scale (STSSS), the Yale Global Tic Severity Scale (YGTSS), the self-rated Tourette Syndrome Symptom List (TSSL), and a videotape-based rating scale. Results Seven patients dropped out of the study or had to be excluded, but only 1 due to side effects. Using the TS-CGI, STSSS, YGTSS, and video rating scale, we found a significant difference (p Conclusion Our results provide more evidence that THC is effective and safe in the treatment of tics. It, therefore, can be hypothesized that the central cannabinoid receptor system might play a role in TS pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum
Gerdeman, G., & Lovinger, D. M. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.1.468 · Cited by 433
A Functional Neuroanatomy of Tics in Tourette Syndrome
Stern, E., Silbersweig, D. A., Chee, K.-Y., Holmes, A., Robertson, M. M., Trimble, M., Frith, C. D., Frackowiak, R. S. J., & Dolan, R. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.741 · Cited by 333
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Metadata
- Authors
- Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 459-465
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1981252279
- Cited by
- 270
- References
- 29
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 13 · 2023: 17 · 2022: 27 · 2021: 15 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 6 · 2013: 5 · 2012: 10
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- delta-9-tetrahydrocannabinol, Tourette syndrome, tics, cannabis, tic reduction, drug safety, Tourette syndrome treatment
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Tourette Syndrome, Humans, Male, Middle Aged, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Receptors, Drug, Severity of Illness Index, Dronabinol, Treatment Outcome, Tics, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial. https://app.cochat.ai/papers/10.4088/jcp.v64n0417
- The paper
- Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n0417
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.